Coverart for item
The Resource Early phase cancer immunotherapy, Sandip Pravin Patel, Razelle Kurzrock, editors

Early phase cancer immunotherapy, Sandip Pravin Patel, Razelle Kurzrock, editors

Label
Early phase cancer immunotherapy
Title
Early phase cancer immunotherapy
Statement of responsibility
Sandip Pravin Patel, Razelle Kurzrock, editors
Contributor
Subject
Language
eng
Summary
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy
Member of
Cataloging source
EBLCP
Dewey number
  • 616.99/406
  • 610
Index
no index present
LC call number
RC271.I45
Literary form
non fiction
Nature of contents
dictionaries
http://library.link/vocab/relatedWorkOrContributorName
  • Patel, Sandip Pravin
  • Kurzrock, Razelle
Series statement
Current Cancer Research
http://library.link/vocab/subjectName
Cancer
Label
Early phase cancer immunotherapy, Sandip Pravin Patel, Razelle Kurzrock, editors
Instantiates
Publication
Note
""3.3.1.3 PD-L1 Expression in Melanoma""
Antecedent source
file reproduced from an electronic resource
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • ""Preface""; ""Immunotherapy: Transforming Cancer Care""; ""Contents""; ""Chapter 1: Primer on Cancer Immunotherapy and the Targeting of Native Proteins""; ""1.1 An Intersection of Oncology and Immunology""; ""1.2 Innate and Adaptive Immunity""; ""1.3 Orchestrating Adaptive Immunity""; ""1.4 Immunobiology of Cancer Immunotherapy""; ""1.5 Biomarkers and Diagnostics in Immuno-oncology""; ""1.6 Targeting Native Proteins Within Cellular Networks""; ""References""; ""Chapter 2: Pharmacokinetics and Pharmacodynamics of Immunotherapy""; ""2.1 Introduction""
  • ""2.2 Immune Checkpoint Inhibitors""""2.2.1 Anti-CTLA-4 Antibodies""; ""2.2.1.1 General ADME/Preclinical Pharmacokinetics""; ""2.2.1.2 Ipilimumab""; ""Description and Human Dosing""; ""Human Pharmacokinetics""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.1.3 Tremelimumab""; ""Description and Human Dosing""; ""Human Pharmacokinetics""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2 Anti-PD-1 and PD-L1 Antibodies""; ""2.2.2.1 Nivolumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""
  • ""Exposure-Response Relationships""""2.2.2.2 Pembrolizumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2.3 Atezolizumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2.4 Durvalumab""; ""Description and Human Dosing""; ""2.2.2.5 Avelumab""; ""Description and Human Dosing""; ""2.3 Immunostimulatory Antibody Therapies""; ""2.3.1 Elotuzumab""; ""2.3.1.1 General ADME/Preclinical Pharmacokinetics""; ""2.3.1.2 Human Pharmacokinetics""
  • ""2.3.1.3 Population Pharmacokinetics""""2.3.1.4 Exposure-Response Relationships""; ""2.3.2 Blinatumomab""; ""2.3.2.1 General ADME/Preclinical Pharmacokinetics""; ""2.3.2.2 Human Pharmacokinetics""; ""2.3.2.3 Population Pharmacokinetics""; ""2.3.2.4 Exposure-Response Relationships""; ""2.4 Immunogenicity""; ""2.5 Studies in Special Populations""; ""2.6 Adoptive Cellular Therapy""; ""2.6.1 Description and Human Dosing""; ""2.6.2 Pharmacokinetics""; ""2.6.3 Pharmacodynamics""; ""2.6.4 Discussion and Future Direction""; ""2.7 Oncolytic Viruses""; ""2.7.1 Description and Human Dosing""
  • ""2.7.2 Pharmacokinetics""""2.7.3 Pharmacodynamics: Immune Profiling and Tumor Immunogenicity""; ""2.8 Conclusion""; ""References""; ""Chapter 3: Immunotherapeutic Biomarkers and Selection Strategies""; ""3.1 Introduction""; ""3.2 Biomarkers: Definition and Clinical Utility""; ""3.3 Immune Cell Markers""; ""3.3.1 PD-L1""; ""3.3.1.1 PD-L1 Expression""; ""3.3.1.2 PD-L1 Assays""; ""Clinical Applications: Trial Data of PD-L1 Expression in Several Tumor Histologies""; ""Clinical Trial Data of PD-L1 Expression as a Predictive Marker in FDA-­Approved Histologies""
Control code
SPR1011200799
Dimensions
unknown
Extent
1 online resource (336 pages).
File format
one file format
Form of item
online
Isbn
9783319637570
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-3-319-63757-0
Quality assurance targets
unknown
Reformatting quality
unknown
Specific material designation
remote
System control number
  • on1011200799
  • (OCoLC)1011200799
Label
Early phase cancer immunotherapy, Sandip Pravin Patel, Razelle Kurzrock, editors
Publication
Note
""3.3.1.3 PD-L1 Expression in Melanoma""
Antecedent source
file reproduced from an electronic resource
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • ""Preface""; ""Immunotherapy: Transforming Cancer Care""; ""Contents""; ""Chapter 1: Primer on Cancer Immunotherapy and the Targeting of Native Proteins""; ""1.1 An Intersection of Oncology and Immunology""; ""1.2 Innate and Adaptive Immunity""; ""1.3 Orchestrating Adaptive Immunity""; ""1.4 Immunobiology of Cancer Immunotherapy""; ""1.5 Biomarkers and Diagnostics in Immuno-oncology""; ""1.6 Targeting Native Proteins Within Cellular Networks""; ""References""; ""Chapter 2: Pharmacokinetics and Pharmacodynamics of Immunotherapy""; ""2.1 Introduction""
  • ""2.2 Immune Checkpoint Inhibitors""""2.2.1 Anti-CTLA-4 Antibodies""; ""2.2.1.1 General ADME/Preclinical Pharmacokinetics""; ""2.2.1.2 Ipilimumab""; ""Description and Human Dosing""; ""Human Pharmacokinetics""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.1.3 Tremelimumab""; ""Description and Human Dosing""; ""Human Pharmacokinetics""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2 Anti-PD-1 and PD-L1 Antibodies""; ""2.2.2.1 Nivolumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""
  • ""Exposure-Response Relationships""""2.2.2.2 Pembrolizumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2.3 Atezolizumab""; ""Description and Human Dosing""; ""Population Pharmacokinetics""; ""Exposure-Response Relationships""; ""2.2.2.4 Durvalumab""; ""Description and Human Dosing""; ""2.2.2.5 Avelumab""; ""Description and Human Dosing""; ""2.3 Immunostimulatory Antibody Therapies""; ""2.3.1 Elotuzumab""; ""2.3.1.1 General ADME/Preclinical Pharmacokinetics""; ""2.3.1.2 Human Pharmacokinetics""
  • ""2.3.1.3 Population Pharmacokinetics""""2.3.1.4 Exposure-Response Relationships""; ""2.3.2 Blinatumomab""; ""2.3.2.1 General ADME/Preclinical Pharmacokinetics""; ""2.3.2.2 Human Pharmacokinetics""; ""2.3.2.3 Population Pharmacokinetics""; ""2.3.2.4 Exposure-Response Relationships""; ""2.4 Immunogenicity""; ""2.5 Studies in Special Populations""; ""2.6 Adoptive Cellular Therapy""; ""2.6.1 Description and Human Dosing""; ""2.6.2 Pharmacokinetics""; ""2.6.3 Pharmacodynamics""; ""2.6.4 Discussion and Future Direction""; ""2.7 Oncolytic Viruses""; ""2.7.1 Description and Human Dosing""
  • ""2.7.2 Pharmacokinetics""""2.7.3 Pharmacodynamics: Immune Profiling and Tumor Immunogenicity""; ""2.8 Conclusion""; ""References""; ""Chapter 3: Immunotherapeutic Biomarkers and Selection Strategies""; ""3.1 Introduction""; ""3.2 Biomarkers: Definition and Clinical Utility""; ""3.3 Immune Cell Markers""; ""3.3.1 PD-L1""; ""3.3.1.1 PD-L1 Expression""; ""3.3.1.2 PD-L1 Assays""; ""Clinical Applications: Trial Data of PD-L1 Expression in Several Tumor Histologies""; ""Clinical Trial Data of PD-L1 Expression as a Predictive Marker in FDA-­Approved Histologies""
Control code
SPR1011200799
Dimensions
unknown
Extent
1 online resource (336 pages).
File format
one file format
Form of item
online
Isbn
9783319637570
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-3-319-63757-0
Quality assurance targets
unknown
Reformatting quality
unknown
Specific material designation
remote
System control number
  • on1011200799
  • (OCoLC)1011200799

Library Locations

Processing Feedback ...